share_log

EF Hutton Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target

Benzinga ·  Sep 5, 2024 14:06  · Ratings

EF Hutton analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment